USANA Health Sciences, Inc.

As of October 31, 2025, USANA Health Sciences, Inc. is considered overvalued with a valuation grade of very expensive, a P/E ratio of 16, and less favorable returns compared to peers and the S&P 500.

As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued due to its lower P/E and EV to EBITDA ratios compared to peers, alongside significant underperformance against the S&P 500.

As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued despite a lower P/E ratio compared to some peers, with significant underperformance relative to the S&P 500, showing a year-to-date return of -41.07% and a three-year return of -59.72%.

As of September 19, 2025, USANA Health Sciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with year-to-date and one-year returns of -17.28% and -23.08%, respectively.

As of September 19, 2025, USANA Health Sciences, Inc. exhibits a bearish trend with moderate strength, indicated by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD and no momentum signals from the RSI.

As of September 11, 2025, USANA Health Sciences, Inc. shows a mildly bearish trend overall, with mixed signals from technical indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -14.07%.

As of August 6, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued, with a P/E ratio of 16, an EV to EBITDA ratio of 4.61, and disappointing stock performance, including a YTD return of -14.07% and a 5-year return of -59.08%.

As of June 27, 2025, USANA Health Sciences, Inc. is fairly valued with a P/E ratio of 16, an EV to EBITDA of 4.61, and a ROCE of 15.36%, lagging behind the S&P 500 with a year-to-date return of -13.26%.

As of October 1, 2023, USANA Health Sciences, Inc. is considered attractive and undervalued with a P/E ratio of 15.2, outperforming the Sensex and trading at a discount compared to Herbalife's P/E of 18.4, while slightly exceeding Nature's Sunshine's P/E of 14.7.

As of November 1, 2023, there is insufficient technical data to assess the current stance of USANA Health Sciences, Inc.

As of March 2022, the management team of USANA Health Sciences, Inc. includes Chairman and CEO Kevin Guest, Lead Independent Director Gilbert Fuller, Senior Director Robert Anciaux, Director John Fleming, and Independent Directors Peggie Pelosi and Feng Peng. They oversee the company's strategic direction and operations.

USANA Health Sciences, Inc. develops and manufactures nutritional and personal care products, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $250 million and a market cap of $567.07 million.

As of Jun 18, USANA Health Sciences, Inc. has a market capitalization of 567.07 million and net sales of 876.24 million with a net profit of 34.81 million over the latest four quarters.